首页 › 基金 › Affinity Asset Advisors, LLC › PRLD

Affinity Asset Advisors, LLC 对 PRLD 的持仓历史

PRELUDE THERAPEUTICS INC · 医疗保健

Affinity Asset Advisors, LLC 在 Q3 2026 的 13F 申报中披露持有 PRLD(PRELUDE THERAPEUTICS INC)2,600,000 股,市值约 US$10.2M,约占其申报组合的 0.47%,在其申报持仓中市值排名第 47 位。 Affinity Asset Advisors, LLC 于 Q3 2026 首次申报该持仓。

最新持仓 (Q3 2026)2.60M 股
申报持仓市值$10.17M
组合权重0.47%
首次申报Q3 2026
最近变动新进
更新于2026-11-14

最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR

Affinity Asset Advisors, LLC 对 PRLD 的持仓演变

Affinity Asset Advisors, LLC 于 Q3 2026 首次披露 PRLD 持仓:2,600,000 股(约 US$10.2M)。

逐季持仓明细

季度股数金额变化
Q3 2026 2.60M $10.17M 新进

关于 PRLD 与 13F 数据

PRLD(PRELUDE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 42 只申报持有 PRLD,申报仓位最大的包括:BAKER BROS. ADVISORS LP (US$54.0M), RA CAPITAL MANAGEMENT, L.P. (US$34.5M), ORBIMED ADVISORS LLC (US$30.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 PRLD 的基金

查看 PRLD 的全部基金持有人 →

常见问题

How long has Affinity Asset Advisors, LLC held PRLD?

Affinity Asset Advisors, LLC has disclosed PRLD holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Affinity Asset Advisors, LLC's current position in PRLD?

As of Q3 2026, Affinity Asset Advisors, LLC holds 2.60M shares of PRLD (PRELUDE THERAPEUTICS INC), valued at $10.17M, representing 0.47% of its reported portfolio and ranking #47.

Has Affinity Asset Advisors, LLC been buying or selling PRLD?

In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC newly opened its position in PRLD.

Which other funds hold PRLD?

Other major institutional holders of PRLD include BAKER BROS. ADVISORS LP, RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.